PAK1 inhibitor

NexGenix Pharmaceuticals is developing a small molecule PAK1 inhibitor for the treatment of Fragile X Syndrome. p21-activated kinase 1 (PAK1) is a serine/threonine kinase that serves as a critical downstream effector for the Rho GTPases Rac and Cdc42, playing a central role in regulating actin cytoskeleton dynamics and dendritic spine morphogenesis. In Fragile X Syndrome, the absence of the Fragile X Mental Retardation Protein (FMRP) leads to the hyperactivation of the PAK signaling pathway, which is linked to the characteristic immature dendritic spine phenotype and associated cognitive and behavioral deficits. By inhibiting PAK1, this therapeutic candidate aims to restore normal synaptic structure and function. The program is currently in preclinical development, building on research that suggests PAK inhibition can reverse structural and behavioral abnormalities in animal models of Fragile X.

Other names

PAK inhibitorp21-activated kinase 1 inhibitorp-21-activated kinase 1 inhibitorp 21-activated kinase 1 inhibitor